Financial firms have issued buy ratings and price targets for Definium Therapeutics stock.
1 report, 1 independent
Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Financial firms have issued buy ratings and price targets for Definium Therapeutics stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
-
Leerink partners
U.S. investment bank
Related events
- Larimar Therapeutics received new analyst coverage from Citigroup, which reiterated a buy rating, alongside market data updates.
- A company is receiving analyst price targets and ratings, concurrent with institutional investors filing required Form 13F reports with the SEC.
- Truist Financial and Citigroup provided buy ratings and price objectives for Crown stock.
- Prudential plc received a reiterated buy rating and price objective from financial firms, including Jefferies Financial Group, as of September 4, 2026.
- Anixa Biosciences disclosed an insider purchase via SEC filing, coinciding with MarketBeat price target changes and a buy rating restatement from Citigroup.